Merus N.V. (MRUS) Reports Q2 Loss of EUR0.40/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Merus Announces Second Quarter 2016 Financial Results and Reviews Recent Clinical Progress and Corporate Developments
August 8, 2016 7:00 AM EDTUTRECHT, The Netherlands, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the second quarter ended June 30, 2016 and provided a review of recent accomplishments and clinical development plans.
We ended the second quarter with 71.1 million of cash and cash equivalents, which provides us with the funding to achieve several development milestones, said Ton Logtenberg, PhD, Chief Executive Officer of Merus. We look forward to reporting on the progress of our lead HER2 x HER3 bispecific candidate, MCLA-128, our... More
